Medical weight management | New York
Zepbound is the brand name for tirzepatide, a once-weekly GIP and GLP-1 receptor agonist. It is FDA approved with diet and physical activity for long-term weight reduction in adults with obesity or adults with overweight and at least one weight-related condition. It is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. The current label includes single-dose pens and vials, multi-dose vials, and single-patient KwikPens.
Zepbound is FDA approved and commercially available in the United States. The current prescribing information was revised in February 2026. Nao Medical provides evaluation and care coordination. A prescription, coverage, dispensing, teaching visit, or administration is never automatic.
The current label has two distinct indications: adult weight reduction and adult moderate-to-severe OSA treatment in patients with obesity. Use with another tirzepatide-containing product or another GLP-1 receptor agonist is not recommended.
The clinician should confirm the adult weight or OSA indication, current BMI, related conditions, prior treatment, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and safe use of the prescribed presentation.
The label starts Zepbound at 2.5 mg under the skin once weekly for four weeks, then increases in 2.5 mg steps after at least four weeks as needed. Weight-management maintenance doses are 5 mg, 10 mg, or 15 mg weekly; labeled OSA maintenance doses are 10 mg or 15 mg weekly.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy in diabetes, hypersensitivity, and safe use of the specific pen or vial. OSA care should also track sleep symptoms and sleep-medicine follow-up.
A brand name is not enough to determine whether treatment is appropriate. The clinician must connect the label to the patient's diagnoses, current medicines, prior treatment, laboratory results, preferences, and coverage.
The clinician should confirm the adult weight or OSA indication, current BMI, related conditions, prior treatment, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and safe use of the prescribed presentation.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy in diabetes, hypersensitivity, and safe use of the specific pen or vial. OSA care should also track sleep symptoms and sleep-medicine follow-up.
Nao Medical must confirm device-specific teaching, weight and OSA intake, payer pathways, adverse-effect triage, follow-up, and sleep-medicine coordination before public scheduling begins.
Zepbound is not approved for every person who wants weight loss or for every sleep complaint. OSA treatment requires the labeled combination of moderate-to-severe OSA and adult obesity. A prescription does not guarantee supply or coverage.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
The sequence protects safety and keeps a product request from bypassing diagnosis, records, monitoring, access, or referral needs.
The clinician reviews weight history, prior treatment, current medicines, related conditions, pregnancy plans when relevant, and the patient's goals.
The visit addresses label criteria, contraindications, interactions, side effects, nutrition, activity, and whether another treatment path is more appropriate.
If a prescription is appropriate, the team discusses the dosage form, administration instructions, coverage process, and follow-up. Approval and supply are not guaranteed.
Follow-up considers response, tolerability, adherence, dose changes, related conditions, and whether treatment should continue or change.
Choose a nearby Nao Medical clinic as a starting point for evaluation or care coordination.
Capability boundary: these location cards do not establish that a medicine, device, laboratory test, injection, or specialty workflow is available at every site. Confirm the exact service before travel.
Bronx
932 E 174th St, Bronx, NY 10460
A place to begin evaluation and care coordination near West Farms, Crotona Park East, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
37-15 23rd Ave, Astoria, NY 11105
A place to begin evaluation and care coordination near Astoria, Ditmars, East Elmhurst, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Bronx
2063A Bartow Ave, Bronx, NY 10475
A place to begin evaluation and care coordination near Co-op City, Pelham Bay, Baychester, and nearby Bronx neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
A place to begin evaluation and care coordination near Crown Heights, Prospect Heights, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
A place to begin evaluation and care coordination near Hicksville, Plainview, Bethpage, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
A place to begin evaluation and care coordination near Jackson Heights, Elmhurst, Corona, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
A place to begin evaluation and care coordination near Jamaica, Briarwood, Richmond Hill, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Queens
30-07 36th Ave, Astoria, NY 11106
A place to begin evaluation and care coordination near Long Island City, Astoria, Sunnyside, and nearby Queens neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Long Island
135 Mineola Blvd, Mineola, NY 11501
A place to begin evaluation and care coordination near Mineola, Garden City, Westbury, and nearby Nassau County communities. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Manhattan
259 1st Ave, New York, NY 10003
A place to begin evaluation and care coordination near StuyTown, the East Village, Gramercy, and nearby Manhattan neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
A place to begin evaluation and care coordination near Williamsburg, Greenpoint, Bushwick, and nearby Brooklyn neighborhoods. Call first to confirm the right visit. This card does not confirm product stock, testing, teaching, dispensing, or administration capability.
Compare care options, prepare for an evaluation, and connect medication questions with broader care.
Explore Nao Medical's broader weight-management program and treatment options.
Review the condition-specific pathway without duplicating broad Zepbound content.
Confirm whether symptoms and clinical context support testing.
Compare a semaglutide treatment with a distinct label and indications.
Review a daily oral option with different administration and interactions.
Answers reflect the current official sources and the limited evaluation-and-coordination scope described above.
These sources support product identity, approval, current labeling, availability, and clinical boundaries. They do not prove Nao Medical site capability or health-plan coverage.
Current weight and OSA indications, dose escalation, presentations, contraindications, and safety information.
Open official sourceOSA approval, eligible population, and treatment context.
Open official sourceCurrent commercial presentation and U.S. availability context.
Open official sourceSource and label check completed August 1, 2026. Named clinical and operations review is still pending.
Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in 2026. Weight treatment should follow the medicine's approved indication while keeping metabolic health, menstrual history, contraception, pregnancy goals, emotional wellbeing, and specialist needs visible.
Zepbound is evaluated under its chronic weight-management indication, not as a treatment approved specifically for PMOS or PCOS.
Connect the Zepbound evaluation with weight-related conditions, current medicines, and reproductive plans.
Review the current oral hormonal contraceptive warning before starting or increasing a dose.
GLP-1-based obesity medicines are not FDA approved to treat PMOS or PCOS itself. A clinician must confirm general weight-management eligibility, safety, the correct product, and current insurance or pharmacy requirements.
General information only. This information is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 2, 2026 from the sources cited here. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.
(917) 310-3371